Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models

Triple negative breast cancer (TNBC) accounts for over 30% of all breast cancer (BC)-related deaths, despite accounting for only 10% to 15% of total BC cases. Targeted therapy development has largely stalled in TNBC, underlined by a lack of traditionally druggable addictions like receptor tyrosine k...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacob, Sheeba, Turner, Tia H, Cai, Jinyang, Floros, Konstantinos V, Yu, Ann K, Coon, Colin M, Khatri, Rishabh, Alzubi, Mohammad A, Jakubik, Charles T, Bouck, Ynes M, Puchalapalli, Madhavi, Shende, Mayuri, Dozmorov, Mikhail G, Boikos, Sosipatros A, Hu, Bin, Harrell, J Chuck, Benes, Cyril H, Koblinski, Jennifer E, Costa, Carlotta, Faber, Anthony C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Biological, Health, and Medical Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802478/
https://www.ncbi.nlm.nih.gov/pubmed/36712364
http://dx.doi.org/10.1093/pnasnexus/pgac232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802478/
https://www.ncbi.nlm.nih.gov/pubmed/36712364
http://dx.doi.org/10.1093/pnasnexus/pgac232

Ejemplares similares